tradingkey.logo

Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension

ReutersMar 10, 2025 11:02 AM

- Mineralys Therapeutics Inc MLYS.O:

  • MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM LAUNCH-HTN AND ADVANCE-HTN PIVOTAL TRIALS OF LORUNDROSTAT FOR THE TREATMENT OF UNCONTROLLED OR RESISTANT HYPERTENSION

  • MINERALYS THERAPEUTICS INC: ADVANCE-HTN MET ITS PRIMARY ENDPOINT

  • MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT

  • MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT

  • MINERALYS THERAPEUTICS INC: LORUNDROSTAT DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE IN BOTH PIVOTAL TRIALS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI